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symptomatic anemia after having an ofﬁce endometrial biopsy. The
patient had regular menses until one month before presentation,
when she began to have continuous light bleeding and crampy lower
abdominal pain. In the ED, pelvic exam demonstrated a friable, yellow
mass occupied the upper vagina. A thin rim of the cervix was palpated
around the mass, and the uterus was enlarged. An abdominopelvic CT
scan revealed a 9.2 × 8.4 × 9.2 cm intra-uterine mass with cystic and
solid components and foci of gas and an adnexal soft tissue mass.
Multiple biopsies of the mass showed only ﬁbrin clots and necrotic
matter. Following stabilization as an inpatient, the patient underwent1. Introduction
Carcinosarcoma (CS), also known as malignant mixed Mullerian
tumor (MMMT), of the uterus is a rare malignancy accounting for less
than 4% of all uterine cancers (Arend et al., 2011). The tumor is charac-
terized asmixture of carcinomatous and sarcomatous elements. There is
considerable diversity in the histological types of the tumor elements.
The carcinomatous component is most commonly serous or high-
grade endometrioid, while the sarcomatous component may display a
wide range of morphology, such as leiomyosarcoma and rhabdomyo-
sarcoma, but is generally poorly differentiated (de Jong et al., 2011).
Uterine CS is considered a Type II epithelial endometrial malignancy
with high rates of p53 mutations, like other high-grade endometrial
cancers. The cancer is often advanced at presentation and follows an
aggressive clinical course associated with poor survival rates.
We present an unusual case of uterine CS exhibiting low-grade
histology in both the carcinomatous and sarcomatous components in
a patient who presented with advanced disease with rapid progression.2. Case report
2.1. Clinical presentation
A52-year-old gravida 2, para 1, perimenopausal female presented to
the emergency department (ED) with vaginal bleeding andology, Department of Obstetrics
th Street, Suite J130, New York,
. This is an open access article underan exploratory laparotomy, radical abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy and pelvic lymphadenectomy.
A metastatic tumor implant measuring 7.5 × 6.5 × 2.5 cm was superﬁ-
cially attached to the small bowel and was excised. Intraoperative
frozen section revealed a sarcomatoid malignancy.
2.2. Pathology
Macroscopic examination revealed a 420 g uterus with distended
endometrial cavity ﬁlledwith yellow-tan necrotic material. Microscopic
examination showed very unusual and intriguing histology. Essentially,
the tumor was composed of two components: low-grade sarcomatous
component resembling stromal sarcoma and carcinomatous compo-
nent composed of well to moderately differentiated endometrioid ade-
nocarcinoma. The two components were sharply demarcated (Fig. 1)
without comingling interface. The tumor was extensively necrotic. The
sarcomatous componentwas immunoreactive for CD10which support-
ed the diagnosis. Although this tumor met the criteria for CS, the histo-
logic ﬁndings were very unusual since these are typically composed of
high-grade sarcomatous and carcinomatous elements. In addition, the
two components in CS are often merging, which was not present in
this case. It also appeared that the two components had separatemet-
astatic potential since the small bowel metastases were morphological-
ly similar to sarcomatous component (Fig. 1b) andmetastatic foci in the
omentum and ovary were composed of carcinoma only (Fig. 1c). The
carcinomatous component expressed estrogen- and progesterone-
receptor, but the sarcomatous component was negative for both.
2.3. Post-operative Course
After an uneventful post-surgical recovery, the patient initially re-
ceived 3 cycles of intravenous carboplatin-paclitaxel chemotherapy.
After the last cycle, the patient had worsening abdominal pain and athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. a. Sharply demarcated component of well tomoderately differentiated carcinoma (solid arrow) and endometrial sarcoma (dotted arrow). The boundary between the solid and dot-
ted arrows denotes the biphasic tumor. b. Sarcomatous componentwith low-grade features (Olympus BX41, 10×). c.Well to moderately differentiated carcinoma (Olympus BX41, 10×).
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omental implants, consistent with peritoneal carcinomatosis. An
image-guided core biopsy was performed to conﬁrm the pathology
given rapid progression; this conﬁrmed that the intraperitoneal lesions
were the sarcomatous component consistent with the primary uterine
tumor. The patient subsequently received intravenous ifosfamide/
mesna/paclitaxel and experienced symptomatic progression of disease
after 5 cycles. Her disease was also refractory to carboplatin-pegylated
liposomal doxorubicin (PLD). At the time of last contact, the patient en-
rolled in a phase I clinical trial of an immune-therapeutic agent, TRX518,
the humanized, Fc disabled, anti-human GITR (glucocorticoid-induced
tumor necrosis factor receptor) monoclonal antibody. One year after
the initial diagnosis, the patient passed away from disease progression.
2.4. Genetic testing
The patient had a strong family history of cancer, including her
mother who survived uterine cancer (29 years old), 2 maternal aunts
diagnosed with breast cancer (48 years old, 50 years old), maternal
cousin diagnosed with breast cancer at age 30 and ovarian cancer at
age 45, and father diagnosed with prostate cancer (age 70+). The
maternal cousin with breast and ovarian cancer was diagnosed with a
5677insA BRCA-1 mutation. It is not known if other family members
have undergone genetic testing. The patient's 25-gene myRisk™ panel
(Myriad Genetics) was negative for any germline mutations.
Both the sarcomatous and carcinomatous tumor samples were
evaluated for somatic genetic mutations through the institutional
precision medicine laboratory. Mutations in KRAS, PTEN, and ARID1A
were detected in the sarcomatous component. In addition, a large
scale ampliﬁcation was found in FCGR2B, which is the Fc fragment of
IgG and a low-afﬁnity IIb receptor for CD32. In the carcinomatous
component, PTEN and NFE2L2 (nuclear-factor (erythroid-derived 2)-
like 2) missense mutations were detected.
3. Discussion
We present an unusual case of uterine CS where both the sarcoma-
tous and carcinomatous components showed low-grade pathology.
This patient's clinical course was very aggressive with chemotherapy-
resistant disease. In the subsequent discussion, we will present a brief
clinical review of uterine CS, discuss the known molecular alterations
in this tumor, and the emerging role of germline and somatic genetic
testing.
The primary treatment of all endometrial cancers, including CS, is
surgery (Arend et al., 2011). Adjuvant therapies, such as radiotherapy,
chemotherapy, or hormonal therapies, may be offered, but there is no
consensus on their use. Surgical treatment includes laparotomy or
laparoscopy with total abdominal hysterectomy, bilateral salpingo-
oophorectomy and surgical staging including pelvic and periaorticlymph node dissection and omentectomy. Surgical cytoreduction in
cases of advanced intraperitoneal disease has shown to beneﬁt progres-
sion free survival in other hig-grade endometrial cancers (Moller et al.,
2004). Given the rarity of uterine CS, efforts supporting surgical
cytoreduction are extrapolated from other uterine carcinoma and soft
tissue sarcoma literature. Randomized cooperative group trials have
shown efﬁcacy of doublet-based initial chemotherapy in uterine CS.
These agents include cisplatin–ifosfamide (CI), ifosfamide–paclitaxel
(IP), and carboplatin–paclitaxel (CP) (Einstein et al., 2012; Powell et al.,
2010; Homesley et al., 2007; Sutton et al., 2005). CI and IP have an overall
response rates of 32% and54%, respectively (Homesley et al., 2007; Sutton
et al., 2005). Regardless, the mean progression-free beneﬁt of CI was 4
months vs 6 months with IP (Homesley et al., 2007; Sutton et al., 2005).
Given the high rates of grade 3–4 toxicity and no beneﬁt of overall surviv-
al, retrospective and phase II clinical trial data support the use of CP as the
primary therapy in chemotherapy-naïve patents; response rate in a phase
II trialwas 54% (13% complete, 41%partial) (Powell et al., 2010). Results of
a phase 3 randomized trial comparing IP vs CP are currently pending
(ClinicalTrials.gov Identiﬁer: NCT00954174).
Given that CSs are heterogeneous tumors, there are several theories
of their pathogenesis, including the collision andmonoclonal origin the-
ories. The collision theory states that the epithelial and sarcomatous
components arise independently of each other in the uterus (Arend
et al., 2011). The current belief is that of the monoclonal hypothesis
where a single clone differentiates into the epithelial (carcinomatous)
and the sarcomatous component (Arend et al., 2011). Further analyses
show that when CS metastasizes outside the uterus or recurs, it is the
epithelial component that is likely present in those implants (de Jong
et al., 2011). Our patient's pathology was distinct in that at the time of
initial surgery, both the carcinomatous and the sarcomatous compo-
nents were present outside the uterus. When she experienced disease
progression, the peritoneal disease was also sarcomatous. The reported
casemay be a rare presentation of a biphasic epithelial and sarcomatous
tumor which behaved independently of each other.
The somatic mutation proﬁle of this patient's tumor is also unique
for uterine CS. Uterine CS is considered a type II endometrial cancer,
with high rates of p53, FBXW7, and PIK3CA mutations such as those
found in serous endometrial cancers (Kandoth et al., 2013; Bashir
et al., 2014). In contrast, low proliferative endometrioid endometrial
carcinomas commonly have somatic mutations in PTEN, PIK3CA,
ARID1A, KRAS, and ARID5B (Kandoth et al., 2013). The molecular proﬁle
of this patient's tumor makes it a grade 1 tumor, further indicating that
this could be a biphasic tumor. There is a dearth of published literature
in themolecular proﬁles of the sarcomatous and carcinomatous compo-
nents of uterine CS. One study indicated that DNA mismatch-repair
genes were absent in both the sarcomatous and carcinomatous compo-
nents in 21% of tumor samples (Taylor et al., 2006). This was not detect-
ed in the proﬁle of our patient's tumor. In addition, themolecular proﬁle
of the tumor showed any actionable agents and did not support the use
11T. Clearman et al. / Gynecologic Oncology Reports 14 (2015) 9–11of targeted therapies for off-label or in-clinical trial. High dose proges-
terone and anti-estrogen therapieswere not considered since the sarco-
matous component, which was the burden of recurrent disease, did not
express these receptors.
In summary, we report a unique pathological type of uterine
carcinosarcoma composed of low-grade epithelial and sarcomatous
components. These tumors are different from hereditary cancer
syndromes. The patient is a true negative even though her family has
homologous-recombination deﬁcient breast and ovarian cancer
syndromes. Molecular proﬁling of the tumor further characterizes the
unique qualities of this tumor. Further understanding of molecular
proﬁles and somatic mutations will help develop a classiﬁcation system
for uterine carcinomas and may lead to targeted therapy trials.Conﬂict disclosure
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